NVO - Novo Nordisk A/S - Stock Price & Dividends

Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Insulin, Diabetes, Obesity, Hormone, Growth Hormone, Rare Diseases

Novo Nordisk A/S is a global healthcare company that specializes in the research, development, manufacturing, and distribution of pharmaceutical products. With a presence in over 170 countries, the company operates in two main segments: Diabetes and Obesity Care, and Rare Disease.

The Diabetes and Obesity Care segment focuses on developing innovative treatments for diabetes, obesity, cardiovascular diseases, and other emerging therapy areas. The company offers a range of products, including insulin pens, growth hormone pens, and injection needles, to help patients manage their conditions more effectively.

In addition to its product portfolio, Novo Nordisk A/S also provides smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. This technology enables patients to track their insulin doses and receive personalized guidance, improving their overall health outcomes.

The Rare Disease segment is dedicated to developing treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. By focusing on these niche areas, the company aims to make a meaningful difference in the lives of patients with rare and debilitating conditions.

Novo Nordisk A/S has a long history of innovation, dating back to its founding in 1923. Today, the company is headquartered in Bagsvaerd, Denmark, and has established partnerships with other leading pharmaceutical companies, such as Aspen Pharmaceuticals, to produce insulin products. With a strong commitment to research and development, Novo Nordisk A/S continues to drive progress in the healthcare industry.

For more information about Novo Nordisk A/S and its products, please visit their website at https://www.novonordisk.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for NVO - Novo Nordisk A/S  - Stock Price & Dividends

NVO Stock Overview

Market Cap in USD 576,214m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1982-01-04

NVO Stock Ratings

Growth 5y 95.3
Fundamental 87.9
Dividend 33.3
Rel. Performance vs Sector 0.06
Analysts 4.18/5
Fair Price Momentum 134.32 USD
Fair Price DCF 487.79 USD

NVO Dividends

Dividend Yield 12m 0.87%
Yield on Cost 5y 4.22%
Dividends CAGR 5y 13.71%
Payout Consistency 60.4%

NVO Growth Ratios

Growth 12m 22.39%
Growth Correlation 12m 71.6%
Growth Correlation 3m -47.7%
CAGR 5y 37.20%
CAGR/Mean DD 5y 7.15
Sharpe Ratio 12m 0.58
Alpha vs SP500 12m -7.10
Beta vs SP500 5y weekly 0.74
ValueRay RSI 11.03
Volatility GJR Garch 1y 27.94%
Price / SMA 50 -8.01%
Price / SMA 200 -7.1%
Current Volume 2855.6k
Average Volume 20d 4856.7k

External Links for NVO Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of NVO stocks?
As of October 18, 2024, the stock is trading at USD 118.22 with a total of 2,855,611 shares traded.
Over the past week, the price has changed by +0.59%, over one month by -10.44%, over three months by -12.37% and over the past year by +24.13%.
What are the forecast for NVO stock price target?
According to ValueRays Forecast Model, NVO Novo Nordisk A/S will be worth about 147.3 in October 2025. The stock is currently trading at 118.22. This means that the stock has a potential upside of +24.6%.
Issuer Forecast Upside
Wallstreet Target Price 148 25.2
Analysts Target Price 80.4 -32.0
ValueRay Target Price 147.3 24.6